Atrial fibrillation (AFib) is a common and serious cardiovascular disease associated with significant morbidity and mortality. AFib is the most common arrhythmia in the United States, affecting more than 2.5 million adults, 80% of whom are 65 years and older. In the next 40 years, the prevalence of AFib is projected to more than double to 5.6 million adults. AFib significantly increases the risk of stroke and heart disease, both of which are leading causes of death in the United States. AFib is also associated with significant impairments in patient quality of life. A study published in 2006, researchers estimate the total direct annual medical cost for treatment of AFib patients over and under age 65 is $6.65 billion, with hospitalizations accounting for the largest share.
Even though the risk factors and serious complications of AFib are well known, AFib has not received the same attention as other chronic conditions to improve diagnosis, treatment, and prevention. A program that provides information relating to the cost, consequence and treatment implications would be of great utility to all health care practitioners and health policy makers.
The Accreditation for this program has expired. You may view the program and take the test to evaluate knowledge gained, but no credit can be claimed for participation in this program
This activity has been designed to meet the educational needs of Physicians, Pharmacists, Nurses, Physician Assistants, Nurse Practitioners, and other health care professionals who are interested in managing patients with Atrial Fibrillation as well as understanding the economic impact of Atrial Fibrillation on the U.S. healthcare system..
This program is supported by educational grants from Sanofi-Aventis.
Release Date: November 30, 2010 -- Expiration Date: November 29, 2012
Faculty: Mark Munger, Pharm.D., F.C.C.P., F.A.C.C.
By the end of the session the participant will be able to:
ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As an provider of continuing medical education, it is the policy of the Educational Review Systems (ERS) and ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is our policy to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by Educational Review Systems and/or ScientiaCME.
Faculty Disclosure: Mark Munger, PharmD discloses that he has done Scientific Research for Novartis Pharmaceutical Co., and has received Honorarium for the publication: " Are All ARBs the Same?" from Connexion.
Disclosures of Educational Planners: Steven Sachse is an officer and part owner of ScientiaCME, LLC. ScientiaCME has received grants from Bayer, Edwards Lifesciences, Eisai, Daiichi-Sankyo, Lilly, Merck, Pfizer, Sanofi Aventis, Wolf-Torey Medical.
Commercial Support Disclosure: This program is supported by educational grants from Sanofi-Aventis
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.